Verastem, Inc. (LON:0LOV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 373.15M |
| Revenue (ttm) | 9.95M |
| Net Income (ttm) | -179.37M |
| Shares Out | n/a |
| EPS (ttm) | -2.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,234 |
| Average Volume | 3,543 |
| Open | 8.58 |
| Previous Close | 9.82 |
| Day's Range | 7.68 - 8.69 |
| 52-Week Range | 3.50 - 11.17 |
| Beta | n/a |
| RSI | 46.14 |
| Earnings Date | Nov 4, 2025 |
About Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The... [Read more]
News
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Verastem (VSTM) Reveals Promising Early Results from VS-7375 Clinical Trial
Verastem (VSTM) Reveals Promising Early Results from VS-7375 Clinical Trial
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouragi...
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi...
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem (VSTM) Remains Strong Despite Recent Drop in Share Price
Verastem (VSTM) Remains Strong Despite Recent Drop in Share Price
Verastem (VSTM) Announces Promising Results from KRAS G12D Inhibitor Study
Verastem (VSTM) Announces Promising Results from KRAS G12D Inhibitor Study
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet
The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive,...
Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade)
Verastem's high operational costs and recent rapid share price rise suggest that VSTM stock price is running hot. Read here for an investment analysis.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant...
Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Balyasny Asset Management L.P. Increases Stake in Verastem Inc
Balyasny Asset Management L.P. Increases Stake in Verastem Inc
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive,...
Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
Verastem Non-GAAP EPS of -$0.63 beats by $0.11, revenue of $2.14M beats by $1.02M
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business ...
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem Oncology gets FDA fast track status for cancer drug
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. ...
Verastem: The Market Is Ignoring The Progress
FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promisi...
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...